244 related articles for article (PubMed ID: 30732494)
1. The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M; Steinle A
Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
[TBL] [Abstract][Full Text] [Related]
2. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
3. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
4. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
5. Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
Lazarova M; Steinle A
Front Immunol; 2019; 10():2689. PubMed ID: 31803194
[TBL] [Abstract][Full Text] [Related]
6. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
[TBL] [Abstract][Full Text] [Related]
7. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
8. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
9. New prospects on the NKG2D/NKG2DL system for oncology.
Ullrich E; Koch J; Cerwenka A; Steinle A
Oncoimmunology; 2013 Oct; 2(10):e26097. PubMed ID: 24353908
[TBL] [Abstract][Full Text] [Related]
10. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
Schmiedel D; Mandelboim O
Front Immunol; 2018; 9():2040. PubMed ID: 30254634
[TBL] [Abstract][Full Text] [Related]
11. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
12. NKG2D signaling in cancer immunosurveillance.
López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S
Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398
[TBL] [Abstract][Full Text] [Related]
13. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
Front Immunol; 2018; 9():620. PubMed ID: 29651291
[TBL] [Abstract][Full Text] [Related]
14. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.
Paschen A; Baingo J; Schadendorf D
Eur J Cell Biol; 2014; 93(1-2):49-54. PubMed ID: 24629838
[TBL] [Abstract][Full Text] [Related]
15. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
16. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
19. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
20. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
